EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Mario Masarone iD, Benedetta Maria Motta, Pietro Torre, Marco Aquino, Federica Belladonna, Martina Lombardi, Jacopo Troisi, Marcello Persico

Internal and Emergency Medicine · 2024-11 · 19 (8) · 2293-2307

DOI: 10.1007/s11739-024-03626-3 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Internal and Emergency Medicine, online erschienen am 16.05.2024. Verfasst von Mario Masarone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, SA, Italy. mmasarone@unisa.it. Hauptthemen laut MEDLINE: Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Università degli Studi di Salerno.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic associated steatotic liver disease (MASLD) is the most common liver condition. It is associated with increased liver-related morbidity and mortality, and also with high risk of cardiovascular events (CVD), representing itself an independent risk factor for it. This makes MASLD a presentation of high interest for internal medicine, also because of its association with metabolic syndrome (MetS). It is crucial to assess its risks in a noninvasive way. With the aim of finding specific risk profiles for CVD development in MASLD by performing a noninvasive assessment of: (1) preclinical signs of endothelial dysfunction (ED); (2) clinical assessment of CVD risk by Framingham Heart Risk Score (FHRs); (3) genomic characterization of MASLD associated polymorphisms; (4) specific untargeted metabolomic profiles, we enrolled 466 MASLD patients non-invasively classified in 4 group of liver fibrosis severity (group-A: low-fibrosis risk, group-B: high-fibrosis risk, group-C: MASLD-cirrhosis, group-D: MASLD-HCC) and 73 healthy controls. FHRs was similar in controls and low-fibrosis group and significantly higher in high-fibrosis patients, cirrhosis, and HCC, increasing among classes. At a multivariable regression, FHRs was associated with liver disease severity and diabetes. 38.2% of patients had altered EndoPAT, resembling ED. Patients with high FHRs (> 40%) and ED had different metabolomics compared to those without ED. Our study reveals that a deep, non-invasive characterization of MASLD patients through precision medicine approaches (untargeted metabolomics, SNPs, ED assessment) was able to show a peculiar pattern in MASLD patients with increased CVD risk, mostly correlated with liver disease severity. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHumansFemaleMaleMiddle AgedCohort StudiesMetabolic SyndromePrecision MedicineFatty LiverAgedRisk AssessmentRisk FactorsAdult

Stichwörter der Autor:innen

Cardiovascular riskMASLDMetabolomicsNAFLDSingle nucleotide polymorphisms

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, SA, Italy. mmasarone@unisa.it.
  • Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, SA, Italy.
  • Theoreo srl, Montecorvino Pugliano, SA, Italy.

ORCID-Profile: Mario Masarone

Förderung

  • Ministero dell'Università e della Ricerca
  • Università degli Studi di Salerno

Zitieren

APA

Masarone, M., Motta, B. M., Torre, P., Aquino, M., Belladonna, F., Lombardi, M., Troisi, J., & Persico, M. (2024). Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study. Internal and Emergency Medicine, 19(8), 2293-2307. https://doi.org/10.1007/s11739-024-03626-3

Vancouver

Masarone M, Motta BM, Torre P, Aquino M, Belladonna F, Lombardi M, et al. Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study. Internal and Emergency Medicine. 2024;19(8):2293-2307. doi:10.1007/s11739-024-03626-3

BibTeX
@article{Masarone2024,
  author = {Masarone, Mario and Motta, Benedetta Maria and Torre, Pietro and Aquino, Marco and Belladonna, Federica and Lombardi, Martina and Troisi, Jacopo and Persico, Marcello},
  title = {Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study},
  journal = {Internal and Emergency Medicine},
  year = {2024},
  volume = {19},
  number = {8},
  pages = {2293--2307},
  doi = {10.1007/s11739-024-03626-3}
}
Kostenlos starten →